DDInter1232 DDInter1628
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Mitomycin {u} (Compound) upregulates {v} (Gene) PLK3
PLK3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) downregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) upregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) downregulates {v} (Gene) C2CD5
C2CD5 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) downregulates {v} (Gene) DYRK1A
DYRK1A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) upregulates {v} (Gene) PLK3
PLK3 {u} (Gene) regulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitomycin {u} (Compound) upregulates {v} (Gene) CLK2
CLK2 {u} (Gene) interacts with {v} (Gene) ZNF263
ZNF263 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitomycin (Compound) upregulates PLK3 (Gene) and PLK3 (Gene) is bound by Ruxolitinib (Compound)
Mitomycin (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Mitomycin (Compound) downregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Mitomycin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Mitomycin (Compound) upregulates BLCAP (Gene) and BLCAP (Gene) is downregulated by Ruxolitinib (Compound)
Mitomycin (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is downregulated by Ruxolitinib (Compound)
Mitomycin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Mitomycin (Compound) downregulates DYRK1A (Gene) and DYRK1A (Gene) is bound by Ruxolitinib (Compound) and DYRK1A (Gene) is upregulated by Ruxolitinib (Compound)
Mitomycin (Compound) upregulates PLK3 (Gene) and PLK3 (Gene) regulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Ruxolitinib (Compound)
Mitomycin (Compound) upregulates CLK2 (Gene) and CLK2 (Gene) interacts with ZNF263 (Gene) and ZNF263 (Gene) is upregulated by Ruxolitinib (Compound)